PIK3C3 and colonic neoplasm: Taken together, it appears that inhibiting PIK3C3/VPS34 may significantly boost the anti-colon cancer therapy though additional studies using murine models of CRC progression and therapy resistance are needed and are part of our ongoing investigations.